$IMAX

Imax Insiders Sold Shares Worth Over $2.7M

IMAX insiders sold shares totaling over $2.7M. CFO Natasha Fernandes sold 20,000 shares at $54.63 each, while President Mark Welton sold shares at $54.47 each. Both disclosed their remaining holdings in a regulatory filing.

Original reporting
Published Aug 26, 2026, 8:10 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 27, 2026, 11:11 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Imax Insiders Sold Shares Worth Over $2.7M — source image
Decision brief

The 30-second read

$IMAXNeutralLow
01

Why it matters

The disclosed sales provide fresh data for traders monitoring insider activity, but the amounts are modest relative to market cap.

02

Market read

Routine insider sell‑off; limited trading relevance.

03

What to watch

No change in company fundamentals; sales could be tax‑loss harvesting.

Relevance 4/10Novelty 3/10Timing: post‑market filing

Background

IMAX (NYSE:IMAX) reported insider sales by its CFO and President, totaling $2.7M.

Company-level read

Ticker impact

$IMAXNeutralMedium confidence
Context

SEC Form 4 disclosed CFO Natasha Fernandes and President Mark Welton sold a total of $2.7M in IMAX shares.

Expected impact

Possible modest downside pressure in the near term.

Evidence & confidence

C‑level insiders sold shares worth over $2.5M; while not large enough to trigger a major move, it could influence sentiment.

Market effects

Minimal impact on entertainment/film exhibition sector.

Limited to US market where IMAX trades.

Low

Counterpoint

Insider sales may be routine portfolio diversification, not a negative signal.

Key entities

  • Natasha Fernandes

    Chief Financial Officer & EVP of IMAX

  • Mark Welton

    President, IMAX Global Theatres

Related articles

$IMAXMed

Why IMAX Stock Climbed to a New All-Time High Today

IMAX stock reached a new all-time high on Monday, rising 3.89% to $54.79. The surge was driven by the record-breaking success of The Odyssey, which became the highest-grossing IMAX release. CEO Rich Gelfond expects this to be their best year. Analyst Steve Frankel predicts IMAX will exceed estimates in the second half of 2026, with shares potentially rising to $60. The company's Q2 2026 revenue grew 12% to $103 million, with adjusted earnings up 65% to $0.43 per share.

$IMAXMed

“The Odyssey” Demand Drives IMAX Shares Higher

IMAX reported Q2 2026 revenue of $103M (up 12% YoY) and EPS of $0.43 (up 65%), driven by strong demand for 'The Odyssey'. The stock has gained 42% YTD, with institutional inflows contributing to a 103.5% rise over the past year. IMAX shows strong sales and EPS growth rates of 11.7% and 18.7% respectively over three years, with EPS expected to rise 14% this year.

$IMAXMed

Why IMAX Stock Rallied on Monday

IMAX shares rose about 5% on Monday after the company said Christopher Nolan’s film The Odyssey became the highest-grossing IMAX release of all time. IMAX reported $289 million in ticket sales, plus $37 million in the fourth weekend, and said IMAX theaters account for 26% of total tickets. IMAX added that 70mm locations have grossed over $37 million and presales near $40 million.

$IMAXMed

Why IMAX Stock Soared on Monday

IMAX said The Odyssey helped it post its highest-ever monthly box-office results, with July box-office revenue of $257 million, up 47% from the prior record. Ticket sales for The Odyssey totaled $221 million. IMAX also announced an upcoming run for Spider-Man: Brand New Day and shares closed Monday nearly 7% higher.

$IMAXMed

'The Odyssey' fuels Imax stock to all-time high. CEO calls momentum a 'flywheel'

Imax shares hit an all-time high Monday, up nearly 6%, after box office momentum from Christopher Nolan’s “The Odyssey.” The company said the film is tracking almost double “Oppenheimer” (2023) and generated $221 million globally, about 25% of Universal’s total. CEO Rich Gelfond attributed results to a “flywheel” of theater expansion and recurring cash flow.